GlassScriptPhysician profile
Warren R Abel
NPI 1912939067
$8,977.27
in general payments reported to CMS, 2019-2025
53 companies · $2,278 in 2025
The $2,278 reported for 2025 was more than what 88% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $898 · 2020: $953 · 2021: $478 · 2022: $1,204 · 2023: $1,174 · 2024: $1,992 · 2025: $2,278.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,407 · Education: $37.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,406.96 |
| Education | $37.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,346.58 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,126.64 | 2020-2025 | Airsupra, Breztri, Fasenra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $692.11 | 2019-2025 | Ofev, Jascayd, Spiriva Respimat |
| Actelion Pharmaceuticals US, INC. | $688.60 | 2019-2025 | Opsumit, Uptravi |
| Insmed, INC. | $560.18 | 2023-2025 | Arikayce, Brinsupri |
| Regeneron Healthcare Solutions, INC. | $433.73 | 2019-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $353.81 | 2022-2025 | Glassia |
| Genzyme Corporation | $332.01 | 2020-2025 | |
| United Therapeutics Corporation | $291.06 | 2019-2025 | Tyvaso, Tyvaso, Orenitram |
| Bayer Healthcare Pharmaceuticals INC. | $258.01 | 2019-2025 | |
| Grifols USA, LLC | $256.06 | 2021-2025 | Prolastin-C Liquid |
| Shionogi INC | $240.11 | 2020-2024 | Fetroja |
| Intuitive Surgical, INC. | $229.76 | 2022-2023 | Da Vinci Surgical System |
| Harmony Biosciences LLC | $179.83 | 2020-2025 | |
| Jazz Pharmaceuticals INC. | $160.27 | 2019-2025 | Xywav |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pulmonx Corporation | $159.49 | 2019-2025 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Chartis Catheter |
| Amgen INC. | $149.96 | 2021-2025 | Tezspire |
| Ethicon INC. | $134.21 | 2020 | |
| Baxter Healthcare | $130.86 | 2022-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Monarch Airway Clearance System |
| Merck Sharp & Dohme LLC | $103.76 | 2020-2025 | Winrevair |
| Inogen, INC. | $98.61 | 2022-2025 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Fujifilm Healthcare Americas Corporation | $81.19 | 2023 | Fujifilm |
| Sunovion Pharmaceuticals INC. | $72.05 | 2019-2020 | |
| Ani Pharmaceuticals, INC. | $65.74 | 2025 | Purified Cortrophin Gel |
| Janssen Pharmaceuticals, INC | $65.63 | 2019-2024 | Xarelto |
| Electromed, INC. | $61.86 | 2019-2025 | Smartvest |
| Genentech USA, INC. | $59.51 | 2019-2021 | |
| Vapotherm INC | $56.59 | 2022 | |
| Philips North America LLC | $55.07 | 2019-2020 | |
| Viatris Specialty LLC | $46.15 | 2025 | Yupelri |
| Abiomed | $44.80 | 2024 | Impella |
| Allergan, INC. | $39.25 | 2019-2020 | |
| Gilead Sciences, INC. | $37.97 | 2019 | |
| Pfizer INC. | $33.33 | 2023-2024 | |
| Mylan Specialty L.P. | $32.04 | 2024 | Yupelri |
| Portola Pharmaceuticals, LLC | $30.96 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $30.91 | 2019 | |
| Inspire Medical Systems, INC. | $28.96 | 2024 | Inspire |
| Teva Pharmaceuticals USA, INC. | $26.55 | 2019-2020 | |
| Abbvie INC. | $22.93 | 2025 | |
| Verona Pharma, INC. | $21.75 | 2025 | Ohtuvayre |
| Ambu INC. | $20.28 | 2024 | |
| Lilly USA, LLC | $20.00 | 2025 | Zepbound |
| Covis Pharma Gmbh | $19.83 | 2022 | |
| 3b Medical, INC. | $15.61 | 2024 | Luna |
| Sandoz INC. | $13.84 | 2019 | |
| Inari Medical, INC. | $13.08 | 2019 | |
| Nabriva Therapeutics, Plc | $12.94 | 2020 | |
| Advanced Respiratory, INC | $12.05 | 2020 | |
| Biomerieux INC | $10.75 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Warren Abel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.